Multidrug resistance (MDR) is a critical problem in the chemotherapy of cancers. Human hepatocellular carcinoma (HCC) responds poorly to chemotherapy owing to its potent MDR. Chemotherapeutic drugs primarily act by inducing apoptosis of cancer cells, and defects in apoptosis may result in MDR. Mitochondrial permeability transition (mPT) is implicated as an important event in the control of cell death or survival and mPT represents a target for the development of cytotoxic drugs. This study aimed to investigate the effects of selective opener (Atractyloside glycoside, ATR) and inhibitor (Cyclosporine A, CsA) of mitochondrial permeability transition pore (mPTP) on a CDDP-resistant HCC cell line (SK-Hep1 cells). In this study, a stable MDR phenotype characterization of SK-Hep1 cell line (SK-Hep1/CDDP cells) was established and used to investigate the role of mPTP in MDR. Results suggested that ATR accelerated the decrease of mitochondrial membrane potential (ΔΨm), reduced the Bax activity, and increased the apoptosis of SK-Hep1/CDDP cells; while CsA inhibited mPTP opening, reduced and delayed the decline of mitochondrial membrane potential, and increased the Bax activity, leading to increased tolerance of SK-Hep1/CDDP cells to apoptosis induction. However, mPTP activity had no effect on the expression of MDR1 in cells,meanwhile the P-gp translocation to mitochondria was increased, and functionally activated. In conclusion, selective modulation of mPTP can affect MDR in human HCC cells. Therefore, activation of mPTP may provide a new strategy to sensitize cancer cells to chemotherapeutic drugs and to reverse the MDR in cancer cells.
Introduction
Hepatocellular carcinoma (HCC) is the most common tumor worldwide, and the third most common cause of cancer death, often accompanied with poor prognosis [1] [2] [3] . A majority of patients are surgically un-resectable at the time of diagnosis, and even for those surgery is possible, the risk of recurrence is extremely high. Consequently, chemotherapy is an important strategy for most HCC patients. Cisplatin has been used as a common chemotherapeutic a g e n t f o r H C C .
H o w e v e r , t h e H C C s t i l l p o o r l y r es p o n d s t o C i s p l a t i n d u e t o i t s i n t r i n s i c o r a c q u i r e d mitldrug resistance (MDR) and the survival of HCC
patients is unfavorable [4, 5] . Multidrug resistance (MDR) is a critical problem in the chemotherapy of cancers [6] . MDR describes a phenomenon of cross-resistance of tumor cells to several structurally and functionally unrelated antitumor drugs after exposure to a single cytotoxic drug. But the exact mechanism of MDR remains unclear.
Mitochondria not only provide the essential energy for life activities, but also take part in various s i g n a l t r a n s d u c t i o n s . I n d u c t i o n o f a p o p t o s i s i s a common way in which chemotherapy drugs eliminate tumor cells. Nowadays, mitochondria now represent a novel target in cancer chemotherapy [7] . Regulation of mitochondrial function can not only protect the normal cells from the initiation of apoptosis, but also induce the release of apoptotic proteins leading to apoptosis of tumor cells.
Mitochondrial permeability transition (mPT) is implicated in apoptosis or necrosis as an important event in the control of cell death or survival. Opening of mitochondrial permeability transition pore (mPTP) renders the cancer cells to show the characteristics of apoptosis by promoting the release of apoptotic protein. Thus, modulation of mPTP may provide a new strategy for the reversal of MDR.
In the present study, a MDR hepatocellular carcinoma cell line (SK-Hep1/CDDP) was established to investigate the ro l e o f m P T P i n t h e M D R o f c a n c e r cells. Our study may provide a new strategy for the reversal of MDR in cancer cells.
Materials and methods

Reagents
Cisplatin (CDDP), doxorubicin (DOX), penicillin, streptomycin, propidium iodide (PI), RNase A, Rho123 and Atractyloside glycoside (ATR) were purchased from the Sigma-Aldrich Chemical Co (St. Louis, MO, USA). Vincristine (VCR) was from Shenzhen Main Luck Pharmaceuticals Inc. (Shenzhen, China),5-fluorouracil (5-FU)from Shanghai Xudong Haipu Pharmaceutical Co. Ltd (Shanghai, China), Cyclosporine A( CsA) from Novartis (Sandimmun, Novartis Pharma AG, Stein, Switzerland), Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS) and Trypsin from Invitrogen (Carlsbad, CA, USA). The phospho-glycoprotein (P-gp) MDR1 mouse monoclonal antibody and FITC-conjugated goat anti-mouse IgG were purchased from Santa Cruz B i o t e c h n o l o g y ( S a n t a C r u z , C A , U S A ) , M i t o T r a c k e r Red CMXRos dye from Invitrogen (Molecular Probes, Invitrogen Corp.), JC-1 from Cell Technology Inc., USA, Cell Counting Kit-8 (CCK-8) from Dojindo Molecular Technologies (Dojindo, Japan), Annexin V-FITC/PI apoptosis detection kit from Nanjing KeyGen Biotech Co., Ltd (Nanjing, China), and cell culture supplies from Corning Life Sciences (Lowell, MA, USA). Anti-tumor agents were prepared with complete culture medium immediately prior to use.
Cell line and culture
The human HCC cell line SK-Hep1 cells (purchased from Cell Culture Center, Institute of Biochemistry and Cell Biology, Chinese Academy of Life Sciences, Shanghai) were maintained in high glucose DMEM (DMEM/H) containing 10% (v/v) fetal bovine serum (FBS), penicillin (200 U/mL), and streptomycin (100 μg/mL) at 37°C in a humidified air with 50 mL/L CO 2 . Approximately 1.0x10 5 cells were seeded in a 25-mm dish, and the medium was refreshed 24 h later. Two to three days later, these cells were sub-cultivated following digestion with 0.25 g/L trypsin, and seeded in another 25-mm dish.
Establishment of SK-Hep1 cells resistant to CDDP (SK-Hep1/CDDP)
CDDP-resistant SK-Hep1 (SK-Hep1/CDDP) cells were established by pulse exposure of SK-Hep1 c e l l s t o h i g h c o n c e n t r a t i o n ( 5 μ g / m l ) o f C D D P f o r short periods over 24 h as previously reported [8] . Briefly, SK-Hep1 cells were washed with 0.01 mol/L PBS and grown in CDDP-free growth medium for one to two days. Following washing with PBS, these cells were maintained in a fresh medium. The resistant cells were isolated by limiting dilution of cis-Diaminedichloroplatinum(CDDP). After 4 weeks' incubation at 37°C in a humidified air with 50 mL/L CO2, the cells recovered at an exponential rate and were then sub-cultivated. Once cell confluence reached 60-70%, the procedures above were repeated. The acquired resistance was confirmed when these cells were able to maintain logarithmic growth upon addition of cisplatin to the medium. The CDDP-resistant cells were established 6 months later. 
Cytotoxicity of CDDP determined by CCK-8 assay
The cytotoxicity of CDDP was determined in different groups by CCK-8 assay according to manufacturer's instructions.The absorbance (A) represents t h e n u m b e r o f v i a b l e c e l l s a n d i s d e t e c t e d w i t h e nzyme-linked immunosorbent assay (ELISA; measuring wavelength: 450 nm; reference wavelength: 650 nm) in a microplate reader. Relative inhibition rate was calculated as follow: relative inhibition rate (%) = (1-A of treated well/A of control well)×100%, and the half maximal inhibitory concentration (IC50) was calculated with the SPSS version 13.0 statistic software package. The resistance index (RI) was calculated as follow: RI = IC50 of resistant cells/IC50 of parental cells.
Flow cytometric analysis using Annexin V/PI double-staining
The changes in cell apoptosis were detected with FITC-annexin V/PI double-fluorescence labeling and subsequent flow cytometry (FCM). Cells of each group were seeded into 6-well plate in triplicate at a density of 1×10 5 cells/mL. Following treatment with 10 µg/mL CDDP for 24 h, cells were harvested and cell density was adjusted to 1×10 5 /mL followed by centrifugation at 1500 rpm for 5 min. 
Evaluation of mitochondrial membrane potential (ΔΨm) by JC-1 staining assay
Mitochondrial membrane potential (ΔΨm) was detected with JC-1 mitochondrial membrane potential detection kit following the manufacturer's instructions. Briefly, 5×10 6 cells were collected and re-suspended in 1 mL of medium. After adding 1 mL of working solution of JC-1 dye, the cells were mixed thoroughly and incubated at 37 ℃ for 20 min in dark. The excessive dye was removed by washing with JC-1 staining buffer. Cells were centrifuged at 1000 rpm for 3 min at room temperature, and the supernatant was removed. The cells were then re-suspended in 500 μL of JC-1 staining working solution by slightly shaking and monitored under laser scanning confocal microscope (Leica Tcs SP2, Germany). JC-1 monomer (green fluorescence) has excitation wavelength of 488 nm and emission wavelength of 505~530 nm. When the ΔΨm is low, JC-1 exists mainly in the form of monomer showing green fluorescence. When the ΔΨm is high, JC-1 forms polymers emitting red fluorescence. The average fluorescence intensity of 10 randomly selected visual fields was calculated with IPP softw a r e , a n d t h e r a t i o o f r e d f l u o r e s c e n c e i n t e n s i t y t o green fluorescence intensity indicates the level of ΔΨm. Reduction in this ratio implies a decline in ΔΨm.
Expressions of MDR1 and Bax by Western blot
Cells from different groups were lysed with p r o t e i n l y s i s b u f f e r , a n d t h e c o n c e n t r a t i o n o f t o t a l protein in the supernatant was measured using BCA method. After denaturation by boiling, 20 µg of total p r o t e i n w e r e s e p a r a t e d b y 1 0 % p o l y a c r y l a m i d e g e l electrophoresis and then transferred onto PVDF membrane (Roche) by semi-dry transfer. Blocking was done with 5% non-fat milk at room temperature for 1 h. Then, these membranes were incubated with primary antibodies (1:500 for MDR1 and 1:1000 for Bax) overnight at 4 ℃. A f t e r w a s h i n g w i t h T B S T ( 0 . 0 5 % Tween-20 in TBS), the membranes were incubated with horseradish peroxidase conjugated secondary antibody (l: 10,000) at 37 ℃ for 1 h. The membrane was then washed with TBST, and chemiluminescent s u b s t r a t e E C I w a s u s e d t o v i s u a l i z e t h e b a n d s . The optical density of each band was analyzed with Gel-Pro gel analysis software (Bio-Rad Inc.). Relative protein expressions were expressed as the density ratio of target protein to respective β-actin. The average expression of each protein was calculated from 3 independent experiments.
MDR1 intracellular localization by laser scanning confocal microscopy
For MDR1 immunofluorescence assay, cells were grown on slides in a 6-well plate. Two days later, Mit o T r a c k e r R e d i n D M E M ( 2 0 0 n m o l / L ) w a s a d d e d followed by incubation for 30 min at 37°C, and then cells were washed twice with ice-cold PBS (0.01 mol/L, pH 7.2). The cells were fixed in ice-cold 4% paraformaldehyde for 30 min followed by permeabilization with 0.3 mg/mL Triton X-100 for 30 min at room temperature. These cells were washed twice with 0.01 mol/L PBS and incubated in blocking buffer containing goat serum for 30 min at room temperature. Cells were washed twice with 0.01 mol/L PBS and the expression of MDR1 was determined using the mouse monoclonal anti-P-gp antibody (1:100). The primary antibodies were replaced with IgG isotype control serving negative control. The incubations with primary antibody were carried out in blocking buffer overnight at 4°C. After incubation with primary antibodies, cells were washed 3 times with 0.01 mol/L PBS, and incubated with FITC-conjugated goat anti-mouse antibody (1:50) in dark for 1.5 h at 37°C. Cell nuclei were counterstained with DAPI (4,6-diamidino-2-phenylindole; Sigma-Aldrich, St. Louis, MO, USA) solution (1 μg/mL in PBS) for 5 min at room temperature. After washing with 0.01 mol/L P B S , c e l l s w e r e m o u n t e d o n s l i d e s u s i n g A n t i f a d e Mounting Medium (Beyotime Institute of Biotechnology, Jiangshu, China). Confocal laser scanning microscopic analysis was performed with a Leica TCS SP2 confocal laser imaging system (Leica Microsystems, Wetzlar, Germany). To ascertain the localization of mitochondria, cells were stained with MitoTracker Red CMXRos dye. A merged image of green MDR1 and MitoTracker Red was obtained. To allow quantitative analysis of the relative fluorescence intensity of cells between groups, cells were selected randomly and scanned at more than 3 points. Software Image-Pro Plus Version 6.0 (MediaCybernetics, Bethesda, MD, USA) was used to calculate the mean fluorescence intensity. Average green fluorescence intensity per cell was expressed as the P-gp protein expression.
Functional assay of mitochondrial P-gp
-gauge needle fitted to a syringe. Unbroken cells, large plasma membrane pieces and nuclei were removed by centrifugation at 1000×g at 4°C for 10 min. The resulting supernatant was subjected to centrifugation at 4°C for 20 min at 10,000 × g. The pellet fract i o n ( i . e . m i t o c h o n d r i a ) w a s f i r s t w a s h e d w i t h t h e abo v e b u f f e r A c o n t a i n i n g s u c r o s e a n d t h e n s o l u b ilized in 50 μl of TNC buffer (10 mM Tris-acetate, pH 8.0, 0.5% Igepal CA-630, 5 mM CaCl 2 ). The supernatant was re-centrifuged at 100,000 × g (4°C, 1 h) to generate cytosol.
Mitochondria were suspended in buffer A and kept on ice until the experiment was performed [9] . All imaging experiments were performed at room temperature in buffer A. The whole isolated mitoc h o n d r i a f r o m c u l t u r e d c e l l s w e r e d i v i d e d i n t e s t tubes to evaluate mitochondrial autofluorescence as well as the uptake and the efflux of Rho 123 into and out of organelles. Rho 123 (5 μg/ml) was added to the samples followed by incubation for 4 min at room temperature in dark. After incubation, fluorescence of Rho 123 in mitochondria was measured with a COULTER ® EPICS ™ XL ™ flow cytometer (Beckman Coulter Inc., Brea, CA, USA). To estimate the Rho 123 ef f l u x , m i t o c h o n d r i a e x p o s e d t o R h o 1 2 3 w e r e re-suspended in 2 ml of buffer A and centrifuged for 5 min at 450×g at 4°C, afterwards they were washed once with 2 ml of buffer A, before diluting them in 500 μl of buffer A. Samples were incubated for another 6 min at room temperature to allow Rho 123 efflux from mitochondria. Then, the fluorescence of R h o 1 2 3 w a s d e t e r m i n e d i n e a c h s a m p l e w i t h t h e COULTER ® EPICS ™ XL ™ flow cytometer and measu r e d a t a f l o w r a t e o f 2 0 0 0 e v e n t s / s . E x p e r i m e n t s were performed at least three times.
Statistical analysis
Data were expressed as mean ± SD. Statistical analysis was done with S P S S v e r s i o n 1 3 . 0 s t a t i s t i c software package. Statistical significance between two groups was determined by paired or unpaired Student's t-test. Comparisons between multiple groups were performed by one-way analysis of variance. A value of P<0.05 was considered statistically significant. Table 1 CCK-8 assay also showed both IC50 and RI of SK-H e p 1 a n d S K -Hep1/CDDP cells were decreased after treatment with mPTP agonist ATR, but increased after incubation with mPTP inhibitor CsA, which increased the resistance to CDDP (Table 2) . 
Results
Toxicity of CDDP to human HCC cells
CDDP-resistant SK-Hep1 (SK-Hep1/CDDP) cells were established by pulse exposure of SK-Hep-1 c e l l s t o h i g h c o n c e n t r a t i o n s o f C D D P . A s s h o w n i n
Detection of apoptotic rate by Annexin V/PI double staining
After treatment with 10 µg/mL CDDP for 24 h, the apoptotic rate of SK-Hep1 cells (6.95±0.29%) was significantly higher than that of SK-Hep1/CDDP cells (2.17±0.11%, P<0.01). If CDDP treated cells were incubated with additional 1 µM o f C s A f o r 2 4 h , t h e apoptotic rates of SK-Hep1 cells and SK-Hep1/CDDP cells were significantly decreased (5.11±0.18% and 0.86±0.14%, respectively) when compared with those with CDDP treatment alone (P<0.05). These results suggest that inhibition of mPTP opening can reduce t h e s e n s i t i v i t y o f c a n c e r c e l l s t o C D D P -induced apoptosis. On the contrary, treatment with mPTP agonist (20 µM ATR) increases the apoptotic rates of both types of cells (24.61±1.03% and 6.18±1.13%, respectively), which are also significantly higher than those with CDDP treatment alone. These findings indicate that promoting the mPTP opening can relatively enhance the cellular sensitivity to CDDP-induced apoptosis and increase the apoptosis of drug-resistant cells after CDDP treatment (Fig. 1) .
Protein expression of MDR1 and Bax
The relative expressions of MDR1 and Bax were shown in Fig. 2 . T h e M D R 1 e x p r e s s i o n w a s s i g n i f icantly increased in SK-Hep1/CDDP cells when compared with SK-Hep1 cells (P<0.01), but there were no significant differences in the MDR1 expression after a d d i t i o n o f m P T P a g o n i s t o r i n h i b i t o r . T h e B a x e xpression was markedly decreased in SK-Hep1/CDDP c e l l s w h e n c o m p a r e d w i t h S K -Hep1 cells (P<0.01). A f t e r a d d i t i o n o f C s A , B a x e x p r e s s i o n s i n b o t h SK-H e p 1 c e l l s a n d S K -Hep1/CDDP cells were reduced to 1.47±0.03 and 0.39±0.03, respectively, which were significantly lower than those of untreated cells (P<0.01 and P<0.05, respectively); while the Bax expressions in SK-Hep1 cells and SK-Hep1/CDDP cells were increased to 4.12±0.03 and 0.91±0.03, respectively, which were significantly higher than those of untreated cells (P<0.01), after ATR treatment (Table  3) . 
Detection of ΔΨm by flow cytometry
T h e Δ Ψ m o f b o t h S K -Hep1 cells and SK-Hep1/CDDP cells was decrease significantly (P<0.05) after 24 h of treatment with 10 µg/mL CDDP (Fig. 3 ) . T h e s i m u l t a n e o u s a d d i t i o n o f 1 µM mPTP inhibitor CsA militates the reduction of ΔΨm; while t h e a d d i t i o n o f m P T P o p ener ATR exacerbates the reduction of ΔΨm. Both differences are statistically significant (P<0.05).
Evaluation of MDR1 distribution by laser scanning confocal microscopy
Intracellular distribution of MDR1 was determined by immunofluorescence. Confocal microscopic analysis confirmed that the expression of MDR1 was elevated in SK-Hep1/CDDP cells and SK-Hep1 cells (Fig. 4A) . MDR1 was localized around the nuclear membranes. To further assess the localization of MDR1, a double stain with MitoTracker Red and DAPI was performed. The green fluorescence was ubiquitous. Fig. 4A showed the relative levels of MDR1/P-gp (green fluorescence) in SK-Hep1/CDDP cells (above) and parental SK-Hep1 cells (below) determined by confocal microscopy.
The results of quantitative assessment are shown in Fig. 4B . CDDP-resistant cells had pronounced higher levels of green fluorescence and higher mean o p t i c a l d e n s i t y w h e n c o m p a r e d w i t h S K -Hep1 cells (P< 0 . 0 5 ) . M e a n w h i l e , a f t e r t r e a t m e n t w i t h A T R o r CsA, MDR1/P-gp fluorescence was increased or reduced, respectively. 
Evaluation of P-gp-mediated accumulation and efflux of Rho 123 in cells
Is the P-gp in mitochondria of the cultured cells functionally active? As shown in Table 4 , Rho 123 accumulated in mitochondria of SK-Hep1 cells in a greater amount than in SK-Hep1/CDDP cells and, once Rho 123 was removed from the incubation mixture, fluorescence intensity was more rapidly decreased in the mitochondria of SK-Hep1/CDDP cells when compared with the mitochondria of SK-Hep1 cells. 
Discussion
A CDDP resistant SK-Hep1 HCC cell line was established in the present study. The resistant cells showed an increase of 13.76 folds in the resistance to CDDP as compared to parent SK-Hep1 cells. The resistant cells also highly expressed MDR1 and had decreased expression of apoptotic protein Bax.
MDR1 expression has been considered to be ass o c i a t e d w i t h t h e r e s i s t a n c e t o a d r i a m y cin and vincristine, but not to cisplatin [10, 11] . However, the MDR1 was over-expressed in myelogenous leukemia cells [12] and HCC cell lines [13] after CDDP treatment. Recent studies showed that HCC expressed MRP1, MDR1, MRP3 and breast cancer resistance protein (BCRP/ABCG2), and these proteins render c a n c e r c e l l s t o b e a M D R p h e n o t y p e [ 1 4 , 1 5 ] . I n t h e present study, MDR1 was significantly up-regulated in CDDP -resistant SK-Hep1 cells, suggesting that MDR1 is also involved in the resistance of cancer cells to CDDP.
The regulatory effects of ATR and CsA on the CDDP-induced cytotoxicity were examined in the resistant cells. The apoptotic rate was also decreased in SK-Hep 1/CDDP cells, and their ability to counteract the chemotherapy induced apoptosis was subsequently elevated. After incubation with mPTP agonist (ATR), the IC50, RI, and cell survival rate of both SK-Hep1 cells and SK-Hep1/CDDP cells against CDDP were decreased. This may be as a result of increased apoptosis and reduced cellular ΔΨm. The protein expression of MDR1 was not affected, but the Bax expression was increased. After treatment with mPTP inhibitor (CsA), the IC50, RI, and cell survival rate of SK-Hep1 cells and SK-Hep1/CDDP cells against CDDP were increased, and the apoptotic rate decreased (compared to SK-H e p 1 c e l l s ) . P r o t e i n e xpression of MDR1 was not affected, but the Bax expression was reduced.
MDR is a critical problem in the chemotherapy of cancer. Use of MDR reversal agents in combination with anti-cancer drugs is an important strategy in the chemotherapy aiming to counteract the MDR of canc e r . T h e m e c h a n i s m u n d e r l y i n g t h e M D R o f c a n c e r cells is complicated, and studies suggest that MDR is m a i n l y r e l a t e d t o t w o t y p e s o f c l a s s i c a l m e m b r a n e transporter proteins in the cancer cells [16] . One belongs to the ATP-binding cassette (ABC) transporter superfamily including P-gp/ABCB1, MRP1/ABCC1, and BCRP/ABCG2, which have the energy-dependent pump function and can export a variety of intracellular substrates including the anticancer drugs across the cancer cell membrane [17] . The other belongs to solute carrier transporter superfamily, which controls the intracellular absorption of anticancer drugs. Over-expression of these two types of transporter proteins mediates the drug-resistance of cancer cells. Kojima et al. have reported that over-e x p r e s s i o n o f M D R 1 ( P -gp, ABCB1) in cancer cells can inhibit the release of mitochondrial cytochrome c into cytoplasm and subsequently inhibit the caspase-dependent apoptosis [18, 19] . Similarly, the over-expressi o n o f B C R P / A B C G 2 , a m e m b e r o f ATP-binding cassette transporter protein family, can also enhance the ability of cells to combat with apoptosis [20] . Recently, mitochondria have become one of important targets in screening novel anticancer drugs. Regulation of mitochondrial function can not only protect the normal cells from the initiation of apoptosis, but also induce the release of apoptotic proteins, leading to apoptosis of cancer cells [21] . As a multiprotein complex locating between the inner and outer membranes of mitochondria, mPTP plays a critical role in the apoptosis mediated by the mitochondrial membrane permeability [22, 23] . The escape from and
